MA27665A1 - Triazoles substitues diaryle comme bloqueurs des canaux sodiques - Google Patents

Triazoles substitues diaryle comme bloqueurs des canaux sodiques

Info

Publication number
MA27665A1
MA27665A1 MA28481A MA28481A MA27665A1 MA 27665 A1 MA27665 A1 MA 27665A1 MA 28481 A MA28481 A MA 28481A MA 28481 A MA28481 A MA 28481A MA 27665 A1 MA27665 A1 MA 27665A1
Authority
MA
Morocco
Prior art keywords
compounds
pain
relates
alone
pharmaceutically acceptable
Prior art date
Application number
MA28481A
Other languages
English (en)
Inventor
James P Carey
Prasun K Chakravarty
Michael H Fisher
Brenda Palucki
Min K Park
William H Parsons
Bishan Zhou
Douglas E Frantz
Michael H Kress
Damian Weaver
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA27665A1 publication Critical patent/MA27665A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés triazole substitués par du biaryle, représentés par la formule (I), (II) ou (III), ou des sels acceptables sur le plan pharmaceutique de ceux-ci. L'invention concerne également un procédé de préparation de tels composés et des sels de ceux-ci, ainsi que des compositions pharmaceutiques renfermant une quantité efficace des composés selon l'invention, soit seuls, soit avec un ou plusieurs autres composés actifs sur le plan thérapeutique, et un excipient acceptable sur le plan pharmaceutique. L'invention concerne, en outre, des méthodes de traitement d'états associés à l'activité des canaux sodiques ou engendrés par celle-ci, notamment, par exemple, des douleurs aigues, des douleurs chroniques, des douleurs viscérales, des douleurs inflammatoires, des douleurs neuropathiques, l'épilepsie, le syndrome du côlon irritable, la dépression, l'anxiété, la sclérose en plaques et un trouble polaire, consistant à administrer une quantité efficace des composés selon l'invention, soit seuls, soit conjointement avec un ou plusieurs autres composés actifs sur le plan thérapeutique. L'invention concerne enfin un procédé d'anesthésie locale consistant à administrer une quantité efficace d'un composé selon l'invention, soit seul, soit conjointement avec un ou plusieurs composés actifs sur le plan thérapeutique, et un excipient acceptable sur le plan pharmaceutique.
MA28481A 2003-03-18 2005-09-06 Triazoles substitues diaryle comme bloqueurs des canaux sodiques MA27665A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45595203P 2003-03-18 2003-03-18

Publications (1)

Publication Number Publication Date
MA27665A1 true MA27665A1 (fr) 2005-12-01

Family

ID=33030073

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28481A MA27665A1 (fr) 2003-03-18 2005-09-06 Triazoles substitues diaryle comme bloqueurs des canaux sodiques

Country Status (34)

Country Link
US (2) US7326726B2 (fr)
EP (1) EP1606269B1 (fr)
JP (1) JP4482554B2 (fr)
KR (1) KR100737721B1 (fr)
CN (2) CN101289428A (fr)
AR (1) AR044503A1 (fr)
AT (1) ATE412639T1 (fr)
AU (1) AU2004221885C1 (fr)
BR (1) BRPI0408407A (fr)
CA (1) CA2519252C (fr)
CL (1) CL2004000551A1 (fr)
CY (1) CY1108720T1 (fr)
DE (1) DE602004017438D1 (fr)
DK (1) DK1606269T3 (fr)
EC (1) ECSP056018A (fr)
EG (1) EG25994A (fr)
ES (1) ES2314387T3 (fr)
HR (1) HRP20050816A2 (fr)
IS (1) IS8001A (fr)
JO (1) JO2480B1 (fr)
MA (1) MA27665A1 (fr)
MX (1) MXPA05009847A (fr)
MY (1) MY142651A (fr)
NO (1) NO20054775L (fr)
NZ (1) NZ542205A (fr)
PE (1) PE20041066A1 (fr)
PL (1) PL1606269T3 (fr)
PT (1) PT1606269E (fr)
RU (1) RU2356897C2 (fr)
SI (1) SI1606269T1 (fr)
TW (1) TWI337605B (fr)
UA (1) UA81660C2 (fr)
WO (2) WO2004083190A1 (fr)
ZA (1) ZA200506906B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1587821T3 (da) 2002-12-19 2008-11-10 Scripps Research Inst Sammensætninger og fremgangsmåder til stabilisering af transthyretin og inhibering af transthyretin-fejlfolding
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
DE602004031667D1 (de) * 2003-11-10 2011-04-14 Merck & Co Inc Substituierte trialzole als blocker des natriumkanals
US7868033B2 (en) 2004-05-20 2011-01-11 Foldrx Pharmaceuticals, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
EP1943216B1 (fr) 2005-10-10 2010-06-30 Glaxo Group Limited Dérivés de prolinamide en tant que modulateurs des canaux sodiques
EP2117538A1 (fr) * 2007-01-24 2009-11-18 Glaxo Group Limited Compositions pharmaceutiques contenant du 2-méthoxy-5- (5-trifluorométhyl-tétrazol-i-yl-benzyl) - (2s-phényl-pipéridin-3s-yl-)
DK2118077T3 (en) * 2007-02-08 2015-03-09 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 ACTIVITY
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
PT2464645T (pt) 2009-07-27 2017-10-11 Gilead Sciences Inc Compostos heterocíclicos fusionados como moduladores do canal de iões
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
BR112013028886A2 (pt) 2011-05-10 2016-08-09 Gilead Sciences Inc compostos heterocíclicos fundidos como moduladores dde canal de sódio
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (fr) 2011-07-01 2018-04-28
US9249112B2 (en) 2011-09-16 2016-02-02 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
WO2013131018A1 (fr) * 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Inhibiteurs biaryle du canal sodique
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
US9751869B2 (en) 2013-03-15 2017-09-05 Bristol-Myers Squibb Company LXR modulators
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
JP2020536870A (ja) 2017-10-05 2020-12-17 バイオジェン インコーポレイテッド アルファカルボキサミドピロリジン誘導体の調製方法
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
WO2019171234A1 (fr) * 2018-03-09 2019-09-12 Pi Industries Ltd. Composés hétérocycliques en tant que fongicides
CN108863965A (zh) * 2018-06-25 2018-11-23 青岛科技大学 一锅法制备1,2,4-三氮唑-3-甲酰胺的方法
CN108794413A (zh) * 2018-06-25 2018-11-13 青岛科技大学 一种1,2,4-三氮唑-3-甲酰胺的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875782A (en) * 1907-04-29 1908-01-07 Walter H Cook Fast-nut.
TW226993B (fr) 1992-05-29 1994-07-21 Kumiai Chemical Industry Co
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
IT1292091B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Derivati eterociclici aromatici azotati,procedimento per la loro preparazione e loro impiego come antigestativi,immunosoppressori e
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
CN1353605A (zh) * 1999-03-26 2002-06-12 欧洲凯尔特股份有限公司 芳基取代的吡唑、咪唑、噁唑、噻唑和吡咯及其应用
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
CA2445568A1 (fr) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Derives triazole inhibiteurs des kinases et leurs utilisations
US6797722B2 (en) * 2002-05-03 2004-09-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
NZ537251A (en) * 2002-07-09 2007-02-23 Bristol Myers Squibb Co Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
KR100467668B1 (ko) * 2002-08-07 2005-01-24 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100470075B1 (ko) * 2002-11-21 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
DE602004031667D1 (de) * 2003-11-10 2011-04-14 Merck & Co Inc Substituierte trialzole als blocker des natriumkanals

Also Published As

Publication number Publication date
RU2356897C2 (ru) 2009-05-27
CL2004000551A1 (es) 2005-01-21
US7326726B2 (en) 2008-02-05
AR044503A1 (es) 2005-09-14
IS8001A (is) 2005-08-29
EG25994A (en) 2012-11-28
ES2314387T3 (es) 2009-03-16
PL1606269T3 (pl) 2009-04-30
EP1606269B1 (fr) 2008-10-29
JP2006520782A (ja) 2006-09-14
ATE412639T1 (de) 2008-11-15
PE20041066A1 (es) 2005-01-22
RU2005132168A (ru) 2006-04-27
PT1606269E (pt) 2008-12-16
KR20050109583A (ko) 2005-11-21
AU2004221885C1 (en) 2010-09-23
WO2004083189A1 (fr) 2004-09-30
CA2519252C (fr) 2008-11-18
NO20054775L (no) 2005-12-16
CY1108720T1 (el) 2013-09-04
AU2004221885A1 (en) 2004-09-30
UA81660C2 (ru) 2008-01-25
CA2519252A1 (fr) 2004-09-30
SI1606269T1 (sl) 2009-02-28
AU2004221885B2 (en) 2010-04-22
JO2480B1 (en) 2009-01-20
TW200505876A (en) 2005-02-16
WO2004083190A1 (fr) 2004-09-30
CN1788002A (zh) 2006-06-14
US7572822B2 (en) 2009-08-11
ZA200506906B (en) 2007-02-28
ECSP056018A (es) 2006-01-27
EP1606269A1 (fr) 2005-12-21
JP4482554B2 (ja) 2010-06-16
HRP20050816A2 (hr) 2006-04-30
US20080171777A1 (en) 2008-07-17
MY142651A (en) 2010-12-15
MXPA05009847A (es) 2005-12-05
TWI337605B (en) 2011-02-21
NO20054775D0 (no) 2005-10-17
KR100737721B1 (ko) 2007-07-11
CN101289428A (zh) 2008-10-22
BRPI0408407A (pt) 2006-03-21
US20050119261A1 (en) 2005-06-02
NZ542205A (en) 2008-11-28
DE602004017438D1 (de) 2008-12-11
DK1606269T3 (da) 2009-02-09

Similar Documents

Publication Publication Date Title
MA27665A1 (fr) Triazoles substitues diaryle comme bloqueurs des canaux sodiques
RU2203274C2 (ru) Спироциклические ингибиторы металлопротеаз
TN2009000544A1 (fr) Derives de benzimidazole
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
TN2009000138A1 (fr) Biaryl-ether-urees
IL114171A0 (en) Certain arylsulfonamido-substituted hydroxamic acids
MA31497B1 (fr) Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c
WO2001081312A3 (fr) Methode de traitement se basant sur l'utilisation de derives de phenyle et de biaryle comme inhibiteurs de prostaglandine e
MA27957A1 (fr) Agents derivatifs de quinolinone comme inhibiteurs de tyrosine kinase
MA27937A1 (fr) Dérivés d'indazole 3, 5-disubstitués, compositions pharmaceutiques, et méthodes de médiation ou d'inhibition de la prolifération cellulaire
MA33502B1 (fr) Composés pyrazolopyrimidine inhibiteurs des jak et procédés
MA27095A1 (fr) Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer
ZA200603583B (en) Substituted triazoles as sodium channel blockers
MA27762A1 (fr) Utilisation de derives de 10-hydroxy-10, 11-dihydrocarbamazepine pour le traitement de troubles affectifs
MA32108B1 (fr) Derives d'indazole
MA27716A1 (fr) 4-aminopyrimidine-5-one
MA29566B1 (fr) Composes chimiques
CA2433039A1 (fr) Agent pour le traitement prophylactique et therapeutique de la douleur neuropathique
FR2521134A1 (fr) Urees et thio-urees substituees, leur procede de preparation et leur application therapeutique comme medicaments anti-atherosclereux
FR2405067A1 (fr) Compositions pharmaceutiques contenant des derives monofonctionnels du psoralene pour le traitement des affections cutanees
EA200400523A1 (ru) Производные [[2-(амино-3,4-диоксо-1-циклобутен-1-ил)амино]алкил] кислоты, применяемые для лечения боли
WO1998057925A1 (fr) Augmentation du taux de cholesterol hdl par 2-[(aminothioxomethyl)hydrazono]-2-arylethyle carbamates
LU85348A1 (fr) Nouveaux derives d'acylaminophenols,leur preparation et leur utilisation comme medicaments
US5968975A (en) Elevation of HDL cholesterol by 2-[(aminothioxomethyl)-hydrazono]-2-arylethyl carbamates